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Abstract
Travelers to Asia are at risk for acquiring Japanese Encephalitis (JEV), an arbovirus with high rates of morbidity and
mortality. Recent advances in vaccination resulting in vaccines with low rates of side effects have strengthened the
rationale to vaccinate more travelers to this region, as reflected in many updated national guidelines for prevention
of disease in travelers. Vaccines however still require a complex pre-travel schedule and are costly, often leading to
a requirement or desire for a vaccination option in the destination country. We explore current national guidelines
for prevention of Japanese Encephalitis and seek to provide information on availability of JEV vaccines in various
Asian countries.
Introduction
Japanese encephalitis virus, a flavivirus transmitted by
mosquitoes, is the leading cause of encephalitis in Asia
[1]. The Japanese encephalitis (JE) cycle occurs between
mosquitoes (mainly the species Culex tritaeniorrhynchus)
and vertebrates. Swine and waterfowl play an important
role as amplifying hosts [2]. Humans are a dead end host
and as such there is no human-to-human transmission.
This mosquito species preferentially breeds in rice paddies
and is a dusk and evening feeder. Approximately 99 % of
JE infections are asymptomatic; however, JE in symptom-
atic patients can be a devastating disease with a mortality
of approximately 30 %. Following an incubation period of
4–14 days, symptomatic patients can present with high
fever, chills, headache, myalgia and confusion. In children
gastrointestinal complaints (pain and vomiting) can dom-
inate initially and 75 % will experience seizures [1]. Up to
50 % of survivors will have persistent neurological deficits
and this is particularly important in children as there may
ensue a lifetime of handicap. Children and the elderly are
more at risk of infection [3]. No treatment is available and
thus apart from mosquito bite avoidance, vaccination is
the only reliable method of prevention. Unfortunately in
most countries a multiple injection series of vaccinations
is required for pre-travel prevention. Many travellers fail
to anticipate this and arrive at a clinic with inadequate
time to achieve complete immunity prior to travel. How-
ever, as many patients who are at risk of Japanese Enceph-
alitis have itineraries lasting several weeks to years, an
opportunity to vaccinate the patient during travel exists
that can mitigate the timing difficulties mentioned above.
Hence, a comprehensive list of available vaccines by coun-
try and providers by city would be of value to many travel
clinic providers, who could then counsel their patients on
options for vaccination upon arrival to Asia. We will re-
view the various current guidelines for vaccination and
provide information about availability of various vaccines
in Asia as an aid to the travel medicine provider.
Review
The World Health Organisation reported an estimated
67 900 cases of JE in 2012, however this is likely to be
an underestimate, as reporting depends on the ability to
clinically and serologically diagnose the disease as well
as the availability of surveillance systems [4]. Furthermore
the infectious burden may be vastly underestimated as the
ratio of asymptomatic to symptomatic infections is esti-
mated to be between 1:25 and 1:300 [5].
Two patterns of transmission are recognised – epidemic
and endemic. In Northern areas such as China, Taiwan,
Nepal and north India, epidemic patterns with seasonal
outbreaks linked to increased rainfall are more typical. In
Southern areas such as Indonesia, Cambodia, Southern
Thailand and Timor-Leste the endemic pattern results in
sporadic cases occurring throughout the year [6].
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Substantial progress has been made in JE surveillance
and the introduction of immunisation programmes since
the 1990’s. By 2012, 75 % of countries with transmission
risk were carrying out surveillance programs and 46 %
had a childhood immunisation programme [4]. In coun-
tries such as Nepal, China and Thailand the incidence of
JE is stabilising or decreasing as a result of these measures
[2]. The World Health Organisation states ‘JE vaccination
should be integrated into national immunization sched-
ules in all areas where JE is recognized as a public health
priority. Even if the number of JE-confirmed cases is low,
vaccination should be considered where there is a suitable
environment for JEV transmission, i.e. presence of animal
reservoirs, ecological conditions supportive of virus trans-
mission, and proximity to other countries or regions with
known JEV transmission’ [1]. However it must be remem-
bered that enzoonotic transmission will continue despite a
country having its population fully vaccinated. A review of
cases reported in Japan from 1992–2004 found that 361
cases were recorded, predominantly in unvaccinated older
individuals [7].
JE remains, however, a rare disease in travellers. Esti-
mates vary but an oft-quoted figure is a 1 in 1 million
risk per month. One recent review analysed 21 con-
firmed cases in travellers reported between 1992 and
2008 [8]. Based on Swedish data the authors estimated
an attack rate of 1/400 000 per trip, regardless of type or
length of stay. Other commentators analysed European
data and proposed an overall disease incidence of 1.3
cases per 7.1 million travellers [9]. A recent small sample
of nearly 400 Australian travellers to Asia found no sero-
conversion for JE– however the small numbers make this
difficult to interpret [10].
Most National Vaccination Guidelines have focused on
the length of travel and the time of year when assessing
risk in order to provide recommendations. However an
analysis of the 21 cases mentioned above showed that
70 % of individuals had travelled ‘short term’ (between
10 days and 5 weeks) and 35 % of the cases occurred out-
side of the ‘high risk transmission’ season. For example, of
eleven cases recorded in travellers to Thailand between
1992 and 2008, six occurred outside of the monsoon sea-
son. Of note these were mainly in Southern Thailand
which has a more endemic pattern of transmission.
For some years the principal vaccine available to travel-
lers was the first-generation, mouse brain derived, inacti-
vated Nakayama strain JE-MB (sold as ‘JE-VAX’ or
‘Biken’). This vaccine was associated with a risk of hyper-
sensitivity reactions which occurred at a rate of between
1-17/10 000 vaccinees. More concerning was the rare but
severe, and occasionally fatal, acute disseminated enceph-
alomyelitis temporally associated with the administration
of this vaccine [3]. The vaccine was recommended as a 3
dose schedule of 0, 7 and 30 days, with 100 % of recipients
having neutralizing antibodies at 6 months. In a trial of
boosters, immunity persisted in 21 persons at 2 years who
did not receive a booster, so boosting recommendations
were not clear [11]. JE-MB vaccine is no longer manufac-
tured in the US, Europe, Japan or Australia, however a
version of this, known as ‘Green Cross’ or ‘Boryung ‘from
its Korean manufacturers, is still utilised in some Asian
countries.
In 2009 an expert opinion on vaccination of travellers
against Japanese encephalitis was published. This was in
response to the disease data in travellers and the avail-
ability of newer, safer vaccines. The authors stated that,
with the availability of safer vaccines ‘the focus of travel
counselling on JE risks and prevention can now be di-
rected at the risks of acquiring the disease and its conse-
quences, instead of the risk of the vaccination’ [3].
In 2009 a Vero cell derived inactivated two dose vac-
cine was introduced, JE-VC. It is marketed as IXIARO®
in the US and most other countries, JESPECT® in
Australia and New Zealand and JEEV® in India. JE-VC
vaccine is composed of proteins from inactivated JEV
plus 0.1 % aluminium hydroxide adjuvant. It requires
cold chain storage at 2–8 °C, protection from light, and
cannot be frozen. In the approval trial 96 % of per-
protocol vaccinees developed neutralizing antibody titre
levels thought to be protective at 28 days after the last
dose with development of protective antibodies in as lit-
tle as 7 days after the second dose [11]. The approved
vaccine schedule involves two doses provided 28 days
apart. Side effects were mild and identical to adjuvant
placebo with site reactions in <1 % and headache, myal-
gias, influenza-like illness and fatigue as the most com-
mon findings, occurring in 13–26 % of recipients in the
first week [11]. JE-VC is now approved in the US for
children from 2 months of age [12]. One dose is only
partially immunogenic, 41 % of vaccinees had protective
immunity at 28 days, declining to 26 % at 56 days. How-
ever, it should be noted that a single dose of JE-VC has
been shown to be immunogenic as a booster in those
previously primed with a full course of JE-MB [13] and
thus a full vaccination history should be taken. Guidance
on boosting a full JE-VC series with a JE-VC booster
varies from country to country due to a lack of long
term immunological data and trials and hence is beyond
the scope of this paper. One recent paper however
showed immunity at 6 years when a JE-VC series was
boosted with a 3rd JE-VC vaccination at 1 year, suggest-
ing some durable immunity with boosting [14].
A common problem is travellers attending for consult-
ation too late to receive two doses of JE-VC at the rec-
ommended 28-day interval. Thus a frequently posed
question on the International Society of Travel Medicine
listserv is – “where can my patient get their second dose
of IXIARO® in Asia?” - indeed a review of listserv posts
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2-GW7S-QHCQ-B71I-YM3SYKOTOBXZ). At this stage
JE-VC has only limited availability in Asia, thus, constrain-
ing options for vaccination in the destination country.
An alternative therefore might be acceleration of the
vaccination schedule. This hypothesis has been success-
fully proven in a clinical trial in Hepatitis B vaccines [15].
The data on JE vaccines is not as robust, however there
are some recently reported findings. A recent study con-
cluded JE-VC vaccine given via an accelerated 2-dose regi-
men within one week induced strong immune response
similar to that obtained with the conventional 28 day
schedule, with a satisfactory tolerability profile. This is of
course off label until published and approved by National
bodies but may be considered as a possible alternative to
the traditional schedule where risk of disease outweighs
forgoing vaccination due to lack of time to get immuno-
logic response per established schedules [16].
The previously quoted study suggests 41 % of adults devel-
oped antibodies to JE 28 days after a single dose of JE-VC;
however this dropped to 26 % after 56 days, suggesting one
dose is not an acceptable vaccination strategy for JE-VC [11].
Thus options for last minute travelers are off license
rapid schedules or offering one vaccine with the under-
standing that it is unlikely to offer adequate protection.
In 2012, Imojev, a novel recombinant chimeric virus
vaccine (CV-JE), was licensed in Australia and Thailand.
CV-JE is based on 17D-204 yellow fever vaccine, with 2
genes deleted and replaced with JE pre-membrane (prM)
and Envelope (E) genes from SA 14-14-2 attenuated virus
[17]. It requires cold chain storage at 2–8 °C and protec-
tion from light (http://products.sanofi.com.au/vaccines/
IMOJEV_AUS_PI.pdf). The vaccine expresses prM and E
proteins which are antigenic and stimulate neutralizing
antibodies and cell mediated immunity. Neutralizing anti-
bodies were present in 89 % of vaccinees 28 days after vac-
cination and persisted in 87 % of vaccinees at 60 months
after vaccination (http://products.sanofi.com.au/vaccines/
IMOJEV_AUS_PI.pdf) [18]. This single dose live vaccine
is highly immunogenic (equivalent to 3 dose inactivated
JE-MB) and is currently the preferred vaccine in Australia
due to its longer predicted period of protection and ease
of administration. It should be noted that this is a live vac-
cine and as such is contraindicated in the immunosup-
pressed, and pregnant or breastfeeding women. It is
licensed from 12 months of age onwards and a booster is
recommended after 1–2 years for children under 18 who
have not received previous vaccination with JE-MB
or JE-VC (http://products.sanofi.com.au/vaccines/IMOJE-
V_AUS_PI.pdf). Most common side effects reported in
the approval trial were headache, fatigue, myalgias and
malaise ranging from 17–24 % of vaccinees. Vaccine site reac-
tions occurred in 12 % of recipients (http://products.sanofi.
com.au/vaccines/IMOJEV_AUS_PI.pdf). CV-JE is currently
licensed in Australia, Thailand, Malaysia, the Philippines,
Hong Kong, and Singapore and can be found in expatriate
clinics in a number of other countries in the region. Receiving
the CV-JE vaccination in country could be an attractive op-
tion for some travellers, with awareness that it will take at
least fourteen days to achieve an adequate level of protection.
Japanese Encephalitis Vaccine, Live (JE-LV) (‘Chengdu’
for short after the name of its Chinese manufacturer) is a
live attenuated JE vaccine consisting of SA 14-14-2 attenu-
ated virus, grown in hamster kidney cell culture. It re-
quires cold chain storage at 2–8 °C and protection from
light. This is also a single dose live vaccine and as such
must be given 28 days after other recent live virus vaccines
such as measles or zoster. Neutralizing antibodies are
generated in 90 % of vaccinees according to the WHO
guideline (http://www.who.int/immunization_standards/
vaccine_quality/pq270_vpsar_jevlive_chengdu_12nov13
.pdf). With one study showing 5 year protective immunity
of 96 % in a follow-on cohort in Nepal [19].
Thus taking into account the availability of these newer and
safer vaccines the advice of the Expert Committee comprised
two categories, either advise vaccine or consider vaccine [3].
The ‘Advise’ category reads as follows: Providers should ad-
vise all travellers to areas of Asia where JE virus is transmit-
ted in an enzootic cycle (including Japan) about the risks and
consequences of JE and characteristics of available vaccines.
JE vaccine is recommended for:
 All expatriates
 Repeat travellers who return frequently to the region
or who, cumulatively, have a prolonged duration of
exposure.
 Any individual with a prolonged duration of stay,
independent of itinerary.
 Any individual with a travel itinerary including rural
areas.
 Travellers wishing maximum protection
However, it fails to take into account the necessary
time required to administer the complete vaccine series,
and failure of this information to be widely known at the
level of the general public who are travelling so they can
prepare adequately before their departure, is a common
occurrence in our experience.
The ‘Consider’ vaccination category reads as follows:
Providers should consider vaccinating the following types
of patients
 All other travellers visiting regions with enzootic
transmission during a transmission period, particularly:
– Those with greater outdoors exposure
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– Individuals > 50 years of age
– Children < 10 years of age
– History of chronic conditions such as
– History of solid organ transplant
– Cochlear implants, ventriculoperitoneal shunts




– Chronic renal disease
– Anti-TNF therapy
– Pregnant women (balancing unknown risks
associated with vaccine)
– Individuals known from previous history to be
homozygous for CCR5Delta32 (which has been
shown to increase the risk of symptomatic West
Nile infections) [2]
The recommendations for the second group take into
account host factors that may put individuals more at
risk and do not rely solely on length or season of travel.
Most national immunisation recommendations are less
detailed than this.
International Country Guidelines for the
Administration of JE Vaccine
A review of the readily accessible international guide-
lines revealed the following guidance, (note: all these
countries currently use JE-VC vaccine except Australia
where CV-JE vaccine is also available):
WHO
 JE vaccination is recommended for travellers to
endemic areas with extensive outdoor exposure
during the transmission season [1]
Australia
JE vaccination is recommended for
 Travellers (≥12 months of age) spending 1 month or
more in rural areas of high-risk countries in Asia and
Papua New Guinea, however, as JE has occurred in trav-
elers after shorter periods of travel, JE vaccination
should be considered for shorter-term travelers, particu-
larly if the travel is during the wet season, or anticipated
to be repeated, and/or there is considerable outdoor ac-
tivity, and/or the accommodation is not mosquito-proof
 All other travellers spending a year or more in Asia
(except Singapore), even if much of the stay is in
urban areas.
All travellers to Asia (and other tropical regions) must
be fully aware of the need to take appropriate measures to
avoid mosquito bites. The risk of JE to travellers to Asia is
determined by the season of travel, the regions visited, the
duration of travel, the extent of outdoor activity and the
extent to which mosquito avoidance measures are taken.
Clearly the risk is greater during prolonged travel to rural
areas of Asia during the wet season; it is probably negli-
gible during short business trips to urban areas.
There are also specific recomendations for the Torres
Strait Islands as follows: JE vaccination is recommended for
 All residents (≥12 months of age) of the outer
islands in the Torres Strait
 All non-residents (≥12 months of age) who will be
living or working on the outer islands of the Torres
Strait for a cumulative total of 30 days or more
during the wet season (December to May). Those
visiting only the inner islands, including Thursday
Island, do not require vaccination [20].
United States Centres for Disease Control
 JE vaccine is recommended for travelers who plan
to spend 1 month or more in endemic areas during
the JE virus transmission season. This includes long-
term travelers, recurrent travelers, or expatriates
who will be based in urban areas but are likely to
visit endemic rural or agricultural areas during a
high-risk period of JE virus transmission.
 Vaccine should also be considered for the following:
– Short-term (less than1 month) travelers to
endemic areas during the transmission season, if
they plan to travel outside an urban area and
their activities will increase the risk of JE virus
exposure. Examples of higher-risk activities or
itineraries include: 1) spending substantial time
outdoors in rural or agricultural areas, especially
during the evening or night; 2) participating in
extensive outdoor activities (such as camping,
hiking, trekking, biking, fishing, hunting, or
farming); and 3) staying in accommodations
without air conditioning, screens, or bed nets.
– Travelers to an area with an ongoing JE outbreak.
– Travelers to endemic areas who are uncertain of
specific destinations, activities, or duration of travel.
JE vaccine is not recommended for short-term travelers
whose visits will be restricted to urban areas or times outside
a well-defined JE virus transmission season (www.cdc.gov).
United Kingdom “Green Book’
Travellers to South and South-East Asia and the Far East
should be immunised if staying for a month or longer in
endemic areas during the transmission season, especially
if travel will include rural areas. Other travellers with
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shorter exposure periods should be immunised if the
risk is considered sufficient. For example, those spending
a short period of time in rice fields (where the mosquito
vector breeds) or close to pig farming (a reservoir host
for the virus) should be considered for vaccination [21].
Canada
Generally, IXIARO® is recommended for travel to JE en-
demic/epidemic areas during the risk season:
 For all travellers who spend more than a cumulative
total of 30 days in rural areas (or in urban areas
known to be endemic or epidemic for JE); this might
include longer term travellers or expatriates who,
while based in urban areas, might be expected to
make intermittent short trips to rural areas of risk;
 For travellers who will spend less than a cumulative
total of 30 days in rural areas(or in urban areas known
to be endemic or epidemic for JE) if they expect to
have substantial cumulative activity outdoors (or
indoors if the indoor area does not exclude
mosquitoes), especially during the evening/night.
Generally, IXIARO® use is not recommended for JE
endemic/epidemic areas during the risk season:
 For travellers whose entire itinerary will be in urban
areas (unless the urban areas are known to be
endemic or epidemic for JE);
 For travellers whose visits to rural areas (or urban
areas known to be endemic or epidemic for JE) will be
during the daytime only (http://www.phac-aspc.gc.ca/
publicat/ccdr-rmtc/08vol34/acs-4/index-eng.php).
European Guidelines were not readily accessible to the
authors and as a result an email and telephone survey of
Eurotrop Members was conducted to elucidate the exist-
ence of other national guidelines. The following re-
sponses were provided:
Spain
National recommendations on Japanese Encephalitis
vaccination in travellers exist. However, it is a very
“open” recommendation: Vaccine is recommended for
those travellers with long exposure (cyclist, occupational
exposure, camping…) in risk areas and during seasonal
transmission, especially in areas with risk of floods.
Czech republic
No national recommendations on Japanese Encephalitis
vaccination in travellers exist. However, vaccination is
recommended for travellers with more than four weeks
stay in areas with transmission of JE (some areas only in
the rainy season), especially if they stay in rural areas.
The respondent acknowledged awareness of vaccine
manufacturer recommendation, and that local practices
differ from vaccine indications.
Poland
No national recommendations on Japanese Encephalitis
vaccination in travellers exist.
The vaccination is not available in the country, and it
requires a special import procedure from a manufacturer
signed by the Ministry of Health. The respondent’s insti-
tutional policy recommends vaccination for long stays in
endemic regions of at least 4 weeks duration with excur-
sions to rural areas especially missionaries, soldiers,
round the world travelers, and hunters.
Denmark
National recommendations on Japanese Encephalitis
vaccination in travellers exist, vaccination is recom-
mended for travellers with more than four weeks stay in









Brunei CV-JE CV-JE Multiple
Cambodia CV-JE, JE-LV Pnomh Penh
China JE-LV Beijing


















Philippines CV-JE CV-JE Multiple
Singapore JE-VC, and
CV-JE
South Korea JE-MB Multiple
Thailand CV-JE Multiple
Timor Leste JE-VC Dili
Vietnam JE-MB some Hanoi, Ho Chi
Minh City
CV-JE
Key: JE-VC Vero cell Vaccine (Ixiaro, Jespect, JEEV); CV-JE Chimeric Vaccine
(Imojev); JE-MB Mouse brain vaccine (Green Cross); JE-LV Live attenuated
vaccine (Chengdu)
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Table 2 List of clinics
Country Clinics
Bangladesh Dr. M. A. Wahab MD PhD.





Bhutan No information available. As there is no childhood
immunisation programme and no expatriate clinics
it is unlikely that the vaccine is available.
Brunei CV-JE licensed, widely available
Cambodia International SOS Cambodia Ltd
House 161, Street 51, Phnom Penh
Tel: +855 12 816 911/ 23 216 911
Fax: +855 23 215 811
Email: info.cambodia@internationalsos.com
CV-JE available
Institut Pasteur du Cambodge
No. 5, Monivong Boulevard, 12201 Phnom Penh
Tel : +855 23 428 561
Email: accueil@pasteur-kh.org
JE-LV available.
China JE-LV vaccine widely available.
International SOS Beijing Clinic
Suite 105, Wing 1, Kunsha Building, 16 Xinyuanli,
Chaoyang District, Beijing 100027, China
+86 (0)10 6462 9112
Email: customerservicebj@internationalsos.com
JE-LV available.
Hong Kong JE-VC and CV-JE are licensed and available at
expatriate clinics.
India JE-VC may be available.
Indonesia JE-MB is routinely used.
Expatriate clinics are starting to import CV-JE.
BIMC HOSPITAL Kuta, Jalan Bypass Ngurah Rai 100 X,
Kuta 80361, Bali, Indonesia
Telephone: (+62 361) 761263




Address: Jalan Kemang Raya 87 - South Jakarta
12730 - Indonesia
TEL: +62 21 719 4565
Fax : +62 21 719 8969
Email: info@globaldoctor.co.id
JE-VC (not stocked but can be ordered in).
Japan JE-VC is licensed and widely available
Table 2 List of clinics (Continued)
Laos Vaccine is not generally available however CV-JE is
available at expatriate clinics in Vientiane.
Malaysia CV-JE licensed and widely available.
Myanmar Myanmar International SOS Limited
Dusit Inya Lake Resort, 37 Kaba Aye Pagoda Road
Yangon
Tel: +95 1 657 922
Fax: +95 1 667 866
Email: reception.ygn@internationalsos.com
CV-JE available.
Nepal CIWEC Hospital | Travel Medicine Center Lazimpat
(Opposite British Embassy) Kathmandu, Nepal




Pakistan Vaccine not available
Papua New Guinea Aspen Medical Harbour City, Sir Hubert Murray
Stadium
PO Box 07 Waterfront, Konedobu, NCD, Port
Moresby
Phone: +675 321 02 02
JE-VC available.
Philippines CV-JE licensed and readily available, particularly at
Paediatrician’s Offices.
Singapore JE-VC and CV-JE licensed and readily available.
South Korea JE-MB widely available.
Taiwan: JE-MB available
Thailand CV-JE is readily available in expatriate clinics.
Timor Leste Stamford Medical Services
Rua Martires da Patria, Mandarim, Dili, 670-331-0141
info@stamfordmedical.com
JE-VC available.
Vietnam International SOS Vietnam Ltd
51 Xuan Dieu Hanoi
Tel: +84 4 3934 0666
Fax: +84 4 3934 0556
Email: han.request@internationalsos.com
CV-JE available.
International SOS Vietnam Ltd Ho Chi Minh City
167A Nam Ky Khoi Nghia St, D3 Ho Chi Minh City
Tel: +84 8 3829 8520
Fax: +84 83 829 8551
Email: Sally.Bautovich@internationalsos.com
No vaccine available as of September 2015.
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areas with transmission of JE (some areas only in the
rainy season), especially if they stay in rural areas.
Italy
No national recommendations on Japanese Encephalitis
vaccination in travellers exist. The respondent’s institu-
tional policy recommended vaccination for travel in en-
demic regions and stay in a rural setting for 1 month or
more including if a seasonal pattern is well recognized.
Portugal
No national recommendations on Japanese Encephalitis
vaccination in travellers exist. The respondent’s institu-
tional policy recommended to follow WHO / CDC /
Health Canada recommendations, i.e. Vaccination is rec-
ommended for travellers with more than four weeks stay
in areas with transmission of JE (some areas only in the
rainy season), especially if they stay in rural areas.
Availability of Vaccine in Asia as of May 2015
Clinics in Asian countries listed on the International Soci-
ety of Travel Medicine website, and other clinics known
to the authors as providing care to expatriates and trav-
ellers in Asia, were contacted via email regarding the
availability of each type of vaccine (JE-MB ‘Green
Cross’, JE-VC ‘Ixiaro/Jespect’, CV-JE ‘Imojev’ and JE-LV
‘Chengdu’) in their location. The results of reported
vaccine availability in certain locations follow in Table 1
and below; these findings do not serve as an endorsement
for these facilities or providers. Other references include
the Travel Medicine directory of the International Soci-
ety of Travel Medicine’s website http://www.istm.org/
AF_CstmClinicDirectory.asp.
Conclusions
At least 9 countries now recommend vaccination for a
substantial number of travelers to Asia. These guidelines
generally recommend vaccination with JE-VC or CV-JE.
Unfortunately JE-VC, the most commonly available vac-
cine in North America, Europe and much of the world
requires multiple vaccinations over a month and may not
be suited to last minute travelers. Furthermore, JE-VC has
limited availability in Asia and completing the course
during travel is a logistically difficult option. Many
Asian countries stock alternate vaccines including CV-
JE, JE-MB or JE-LV, which are currently unavailable to
many travelers pre-departure.
Travel clinic providers have options including
 Use of an ‘off-label’ accelerated vaccine schedule
with the tradeoff of possible loss of durable
immunity requiring boosters in the future.
 Contacting one of the few expatriate clinics that
stock JE-VC in Asia and completing the series there.
 Receiving CV-JE or JE-LV in Asia as a 1 shot vaccine
with high and durable immunity that may be delayed
for several weeks after vaccination (ensuring no
contraindications to live vaccine administration)
The last 2 require amendments to the traveler’s itinerary
and obviously are not well suited to a short vacation;
however this type of traveler is at relatively low risk of
acquiring JEV. A traveler with a longer itinerary who is at
higher risk of exposure to JEV should have more flexibility
in their ability to go get vaccinated whilst in Asia.
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